Why Soleno Therapeutics Stock Blasted 9% Higher Today

Core Insights - Soleno Therapeutics is nearing FDA approval for its Prader-Willi treatment, leading to a stock price increase of over 9% [1] - The FDA has determined that an advisory committee meeting is not currently needed for Soleno's new drug application for diazoxide choline (DCCR) [2] - The FDA is expected to make a decision on DCCR by December 27, as it has been designated for priority review [3] - DCCR has received breakthrough therapy designation from the FDA, which may expedite the approval process [4]